TELMISTRUM TRIO

Description

TELMISTRUM TRIO Telmisartan (40mg), Cilnidipine (10mg), Chlorthalidone (12.5mg) TELMISTRUM TRIO is a potent regimen aimed at managing hypertension, particularly in patients for whom monotherapy does not sufficiently control blood pressure. TELMISTRUM TRIO employs different mechanisms to lower blood pressure, offering a broad-spectrum approach that can address various underlying factors contributing to hypertension. Here's a brief overview of each component and the rationale behind TELMISTRUM TRIO : Telmisartan Class: Angiotensin II Receptor Blocker (ARB) Mechanism: Blocks the angiotensin II receptor, leading to vasodilation, reduced aldosterone release, and decreased blood volume, which in turn lowers blood pressure. Benefits: Beyond its blood pressure-lowering effects, Telmisartan offers cardiovascular protection and is beneficial for patients with heart failure or at risk for cardiovascular events. Cilnidipine Class: Calcium Channel Blocker (CCB) Mechanism: Inhibits calcium ions from entering the cells of the heart and blood vessel walls, leading to vasodilation. Cilnidipine uniquely blocks both L-type and N-type calcium channels, which helps in controlling the sympathetic activity that can cause tachycardia and arrhythmias, unlike other CCBs that primarily block L-type channels. Benefits: Offers vasodilatory effects with a potentially lower risk of reflex tachycardia. It's particularly beneficial in patients with renal impairment, as it may offer nephroprotective effects. Chlorthalidone Class: Thiazide-like Diuretic Mechanism: Works by inhibiting sodium and chloride reabsorption in the distal convoluted tubules, causing increased excretion of sodium, chloride, and water, which lowers plasma volume and reduces blood pressure. Benefits: Chlorthalidone is known for its long-acting blood pressure-lowering effects and is associated with a reduction in cardiovascular events. It may be more effective than some other diuretics in preventing heart failure and stroke. Combined Therapy Rationale Comprehensive Blood Pressure Control: By combining an ARB, a CCB, and a diuretic, this regimen targets different pathways involved in blood pressure regulation, which can lead to more significant and consistent blood pressure reduction than monotherapy or dual therapy. Cardiovascular Protection: Each component of the combination offers additional benefits beyond blood pressure control, such as cardiovascular risk reduction and potential nephroprotection. Suitability for Resistant Hypertension: This combination can be particularly effective in patients with resistant hypertension, who do not achieve blood pressure control with standard dual therapy. Considerations and Monitoring Electrolyte Monitoring: Given the diuretic component, it's crucial to monitor electrolytes, particularly potassium levels, to avoid hypokalemia or hyperkalemia. Renal Function: Regular monitoring of renal function is advisable, especially considering the potential for nephroprotection and the risk of renal impairment. Individual Tolerability: The choice of this combination should consider the patient's comorbid conditions, potential side effects, and overall tolerability. For further information please contact: info@sterispharma.com / contact@sterispharma.com call/whatsapp: 8209542042, 8955945010,7877551268, 6377716668, order now: https://www.sterisonline.com/product/telmistrum-trio-133386